BridgeMD
ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion
EU CTIS ID: 2023-508454-26-00
What this study is testing
To assess the efficacy and safety of the use of tirofiban versus aspirin in patients with ischemic stroke secondary to tandem injury, by determining the rate of reocclusion as well as determining the rate of symptomatic bleeding defined as any hemorrhagic transformation associated with a worsening of 4 or more points on the National Institutes of Health Stroke Scale
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with acute ischemic stroke of the anterior territory secondary to a tandem lesion, with an indication for thrombectomy treatment according to the current recommendations of the Clinical Practice Guidelines, and the need for cervical stent placement.
- The intracranial occlusion locations that may be included are: carotid "T", M1 and M2 segments of the middle cerebral artery, segment A1 of the anterior cerebral artery; and in the case that the posterior cerebral artery has fetal origin and is the site of intracranial occlusion.
- ASPECTS (Alberta Stroke Program Early computerized Tomography Score) ≥6.
- Greater than or equal to 18 years of age.
- Signed informed consent.
You likely can't join if
- Patients under 18 years of age.
- Pregnant.
- Patients with intracranial occlusive arteriosclerotic disease or extra or intracranial dissection.
- Documented allergy to acetylsalicylic acid or Tirofiban.
- Personal history of platelet penia (Platelets <100,000)
- Concomitant anticoagulant treatment (with presence of INR (International Normalized Ratio) > 1.7 in case of anti-vitamin K treatment or taking direct oral anticoagulant <48 hours ago)
See the full eligibility criteria
- Patients with acute ischemic stroke of the anterior territory secondary to a tandem lesion, with an indication for thrombectomy treatment according to the current recommendations of the Clinical Practice Guidelines, and the need for cervical stent placement.
- The intracranial occlusion locations that may be included are: carotid "T", M1 and M2 segments of the middle cerebral artery, segment A1 of the anterior cerebral artery; and in the case that the posterior cerebral artery has fetal origin and is the site of intracranial occlusion.
- ASPECTS (Alberta Stroke Program Early computerized Tomography Score) ≥6.
- Greater than or equal to 18 years of age.
- Signed informed consent.
- Patients under 18 years of age.
- Pregnant.
- Patients with intracranial occlusive arteriosclerotic disease or extra or intracranial dissection.
- Documented allergy to acetylsalicylic acid or Tirofiban.
- Personal history of platelet penia (Platelets <100,000)
- Concomitant anticoagulant treatment (with presence of INR (International Normalized Ratio) > 1.7 in case of anti-vitamin K treatment or taking direct oral anticoagulant <48 hours ago)
- Medical history of the patient that carries a high risk of bleeding according to the investigator's criteria.
- Peptic ulcer active in the last 3 months.
- Patients with ASPECTS <6.
- Bilateral strokes or those produced by simultaneous occlusion of an artery in the anterior and posterior territory.
- Patients whose carotid stenosis is due to a re-stenosis or reocclusion of a pre-existing cervical stent.
- Candidate patients for carotid puncture.
- Previous treatment with double antiplatelet therapy for another cause prior to inclusion.
- Severe comorbidity and / or reduced life expectancy.
- Modified Rankin scale (mRS)> 2.
- Severe allergy to contrast medium.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.